Abstract
Molecularly targeting signaling pathways that are involved in the pathogenesis of hematopoietic malignancies may lead to more specific and efficacious therapies. Activation of the RAS signal transduction cascade is a common feature in the molecular pathogenesis of hematologic malignancies. A number of novel agents targeting RAS signaling have been developed over the past decade. This review will focus on these agents, which include inhibitors of RAS post-translational modification (farnesyl transferase (FTase)-, geranylgeranyl transferase-I (GGTase-I)-, isoprenylcysteine carboxylmethyltransferase (ICMTase)-inhibitors, statins, bisphosphonates), and inhibitors of RAF and MEK activity. Although some of these inhibitors (e.g. FTase, RAF and MEK inhibitors) were developed to specifically inhibit RAS signaling, it has become clear that RAS may not be the only critical target of these compounds. This review provides a background on RAS signaling in hematologic malignancies and discusses opportunities to exploit aberrant cancer cell signaling in order to develop better treatment options for patients suffering from these diseases.
Keywords: Farnesyltransferase inhibitors, geranylgeranyltransferase I inhibitors, RAS signaling, hematologic malignancies
Current Drug Targets
Title: Targeting the RAS Signaling Pathway in Malignant Hematologic Diseases
Volume: 8 Issue: 2
Author(s): M. A. Morgan, A. Ganser and C. W. M. Reuter
Affiliation:
Keywords: Farnesyltransferase inhibitors, geranylgeranyltransferase I inhibitors, RAS signaling, hematologic malignancies
Abstract: Molecularly targeting signaling pathways that are involved in the pathogenesis of hematopoietic malignancies may lead to more specific and efficacious therapies. Activation of the RAS signal transduction cascade is a common feature in the molecular pathogenesis of hematologic malignancies. A number of novel agents targeting RAS signaling have been developed over the past decade. This review will focus on these agents, which include inhibitors of RAS post-translational modification (farnesyl transferase (FTase)-, geranylgeranyl transferase-I (GGTase-I)-, isoprenylcysteine carboxylmethyltransferase (ICMTase)-inhibitors, statins, bisphosphonates), and inhibitors of RAF and MEK activity. Although some of these inhibitors (e.g. FTase, RAF and MEK inhibitors) were developed to specifically inhibit RAS signaling, it has become clear that RAS may not be the only critical target of these compounds. This review provides a background on RAS signaling in hematologic malignancies and discusses opportunities to exploit aberrant cancer cell signaling in order to develop better treatment options for patients suffering from these diseases.
Export Options
About this article
Cite this article as:
Morgan A. M., Ganser A. and M. Reuter W. C., Targeting the RAS Signaling Pathway in Malignant Hematologic Diseases, Current Drug Targets 2007; 8 (2) . https://dx.doi.org/10.2174/138945007779940043
DOI https://dx.doi.org/10.2174/138945007779940043 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Conventional Anticancer Therapeutics and Telomere Maintenance Mechanisms
Current Pharmaceutical Design Reversal of Resistance to Oxazaphosphorines
Current Cancer Drug Targets Microtubule-targeting Anticancer Agents from Marine Natural Substance
Anti-Cancer Agents in Medicinal Chemistry Current Metabolomic Methodologies & their Application to Thermal Stress
Current Metabolomics Cellular Therapy for Ovarian Cancer: Experimental and Clinical Perspectives
Current Medicinal Chemistry The Immunoproteasome as a Therapeutic Target for Hematological Malignancies
Current Cancer Drug Targets Pleiotropic Effect of Mahanine and Girinimbine Analogs: Anticancer Mechanism and its Therapeutic Versatility
Anti-Cancer Agents in Medicinal Chemistry Molecular Targeted Therapy of Gastrointestinal Stromal Tumors
Current Cancer Drug Targets Antiproliferative and Proapoptotic Effects of Proteasome Inhibitors and their Combination with Histone Deacetylase Inhibitors on Leukemia Cells
Cardiovascular & Hematological Disorders-Drug Targets Angiogenesis and AngiomiRs in Non-Hodgkin´s Lymphomas
Current Angiogenesis (Discontinued) The Molecular Bases of the Self-Renewal and Differentiation of Leukemic Stem Cells
Current Cancer Therapy Reviews Editorial
Recent Patents on Anti-Cancer Drug Discovery Transition Metal-Based Prodrugs for Anticancer Drug Delivery
Current Medicinal Chemistry Isocitrate Dehydrogenase 2 Inhibitors for the Treatment of Hematologic Malignancies: Advances and Future Opportunities
Mini-Reviews in Medicinal Chemistry CXCR4 Inhibitors: Tumor Vasculature and Therapeutic Challenges
Recent Patents on Anti-Cancer Drug Discovery Heavy Metal Toxicity in Humans and its Preventive and Control Measures
Current Nutrition & Food Science Recent Patents of Gene Mutation Relative to JAK/STAT Pathway and Their Implication in Myeloproliferative Diseases
Recent Patents on DNA & Gene Sequences Central Nervous System Involvement in Pediatric Rheumatic Diseases: Current Concepts in Treatment
Current Pharmaceutical Design Reprogrammed Metabolism of Cancer Cells as a Potential Therapeutic Target
Current Pharmaceutical Design Is there any Role for Splenectomy in Adulthood Onset Chronic Immun e Thrombocytopenia in the Era of TPO Receptors Agonists? A Critic al Overview
Cardiovascular & Hematological Disorders-Drug Targets